Drug intelligence / Profile preview

anti-PD-1 humanized monoclonal antibody

Development stage
Unknown
Lead developer
Anke Bio
Modality
Monoclonal Antibodies → Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

Anti-PD-1 humanized monoclonal antibody is a recombinant humanized monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor. Developed by Anhui Anke Biotechnology, it is designed to bind to PD-1 on the surface of T cells, thereby inhibiting its interaction with ligands PD-L1 and PD-L2. This blockade prevents the inhibitory signaling that tumors use to evade the immune system, effectively restoring T-cell mediated anti-tumor activity. The drug is currently being evaluated in Phase I/II clinical trials in China for the treatment of various advanced malignant solid tumors and lymphomas.

Other names
recombinant anti-PD-1 humanized monoclonal antibody
02

Targets

FCGRT (Neonatal crystallizable fragment receptor)PDCD1 (Programmed cell death protein 1 receptor)FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)

Beyond the preview

Go deeper on anti-PD-1 humanized monoclonal antibody.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-PD-1 humanized monoclonal antibody.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call